+91-9896593699

DRDEEPAKSHUKLA https://www.cancerinfo.in
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

919896539256

Bevacizumab is the first antiangiogenic therapy to be approved in advanced adenocarcinoma lung in combination with chemotherapy. Dose used in different trial was different and varied from 7.5 mg/kg 3 weekly to 15 mg/kg every 3 weeks. Chemotherapy par

Maintenance with PARP inhibitor is the way forward in ovarian cancer:Median PFS in platinum sensitive relapse carcinoma ovary is approximately 10 months.20% of high grade serous carcinoma ovary have somatic or germline mutation in BRCA gene.Sin

Is it possible to avoid chemotherapy in Breast Cancer?Breast cancer is a heterogeneous disease.This heterogeneity was initially assessed by clinical factors comprising of age, stage, grade, hormone-her2nu status and presence or absence of lymphov

Cancer treatment is complex and requires a team of cancer specialist. It is important to keep in mind that cancer is not a single disease and there are about 200 different types of cancer, to add to the complexity each is staged differently and subse

Liquid biopsy in non small cell lung cancer is now being used for detection of EGFR mutation analysis in patients who do not have accessible tissue for conventional testing and based on the platform used for liquid biopsy ie digital v/s nondigital it

Median survival in metastatic carcinoma breast is 2 years.5 year survival is close to 25% (i.e. one out of 4 patients of metastatic breast cancer will be alive at 5 years).New Class of drugs - CDK4 & 6 inhibitor (Palbociclib, Ribociclib) have bee

IMMUNOTHERAPY IN LUNG CANCER- THE FUTURE OF CANCER CARE.Any cancer and lung cancer in particular creates a highly immunosuppressive environment locally i.e. our bodies immune cells are unable to recognize cancer cells.This is made possible by exp

ERA OF PERSONALISED MEDICINE IN METASTATIC ADENOCARCINOMA LUNG:Stage IV adenocarcinoma is not a single disease. Different molecular subtypes of NSCLC have been identified and the treatment approach is different for each subtype.The different mole

services